Vital Therapies, Inc. (NASDAQ:VTL) Director Muneer A. Satter bought 50,000 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were acquired at an average price of $3.53 per share, for a total transaction of $176,500.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Vital Therapies, Inc. (VTL) traded up 6.94% during mid-day trading on Tuesday, hitting $3.85. 251,040 shares of the stock were exchanged. The stock’s 50 day moving average is $2.90 and its 200 day moving average is $3.36. Vital Therapies, Inc. has a 12 month low of $2.25 and a 12 month high of $6.58. The firm’s market cap is $162.50 million.
Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.01. During the same period in the previous year, the business posted ($0.30) EPS. Analysts expect that Vital Therapies, Inc. will post ($1.31) EPS for the current fiscal year.
WARNING: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/2887338/vital-therapies-inc-vtl-director-buys-176500-00-in-stock.html.
A number of analysts have recently commented on the stock. ValuEngine cut shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Raymond James Financial, Inc. assumed coverage on shares of Vital Therapies in a report on Thursday, May 18th. They set an “outperform” rating and a $6.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $8.00.
Several institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP purchased a new position in shares of Vital Therapies during the second quarter valued at $268,000. Goldman Sachs Group Inc. increased its stake in shares of Vital Therapies by 261.4% during the second quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock valued at $676,000 after buying an additional 168,705 shares during the period. Victory Capital Management Inc. increased its stake in shares of Vital Therapies by 1.2% during the second quarter. Victory Capital Management Inc. now owns 2,579,279 shares of the company’s stock valued at $7,480,000 after buying an additional 29,840 shares during the period. Blair William & Co. IL increased its stake in shares of Vital Therapies by 67.2% during the second quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock valued at $289,000 after buying an additional 40,000 shares during the period. Finally, LMR Partners LLP purchased a new position in shares of Vital Therapies during the second quarter valued at $396,000. Hedge funds and other institutional investors own 25.58% of the company’s stock.
About Vital Therapies
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.